Meeting Program 2018

49th Annual Meeting

September 7 - 9, 2018
Hilton Inverness Hotel and Conference Center

note: The program is confirmed 30 days prior to the event.

Friday, September 7
Time Event Location
3:00 pm - 6:00 pm CHECK-IN and REGISTRATION
6:00 pm Welcome Reception
7:00 pm Welcome by PRS President Jeff Reese MD and dinner
8:00  pm Mead Johnson Nutrition Lecturer
Jeff Alberts PhD
Title: Gravid without Gravity: Spaceflight Experiments Yield Insights into Perinatal Development
All of life on Earth evolved in the presence of gravity.  There has long been speculation about theories of gravitational forces in reproductive and developmental processes.  Over several decades the micro-gravity environment of spaceflight has been used to probe into some of these speculations.  Numerous studies have been conducted on unmanned Russian satellites on NASA's Space Shuttle and on the International Space Station.  Previously unknown influences of gravity on mammalian reproduction and development have been revealed.  Moderator: Name
Location
8:45pm Questions and Answers

 

Saturday, September 8
Time Event Location
6:45am - 7:45 am BREAKFAST Location
8:00 am - 8:45am Vanderbilt Lecturer
Sylvain Chemtob MD PhD FRCPC FAAP FCAHS FARVO
Title: Discovery of new IL-1 Receptor - Modulator - prevention of preterm labor and preservation of fetal integrity
Preterm birth (PTB) is a leading cause of neonatal mortality and morbidity worldwide - and surviving infants are at increased risks of lifelong complications.  PTB has been firmly linked to inflammation regardless of infection - specific aetiology or time of birth.  Deleterious inflammation is observed in maternal and fetal tissues and correlates with the severity of perinatal complications.  At present PTB is treated with tocolytics as though t is exclusively a myometrial contractile disorder.  These agents do not address underlying inflammatory processes and are thus vastly ineffective at improving neonatal outcomes.  Of all inflammatory mediators - IL-1 is central to the pathophysiology of PTB and most adverse neonatal outcomes.  Yet current IL-1 receptors antagonists are generally ineffective and considerably immunosuppressive.  We will present novel IL-1-targeting agents effective in relevant-clinical models of PTB - which also preserve fetal/newborn tissue integrity.  Moderator: Member
Location
8:45am - 9:00am Questions and Answers
9:00am - 9:20am Mead Johnson Nutrition Early Career Speaker
Speaker
Title:  xxx
Moderator: Member
Location
9:20am - 9:30am Questions and Answers
9:30am - 9:50am Mead Johnson Nutrition Early Career Speaker
Speaker
Title:  xxx
Moderator: Member
Location
9:50am - 10:00am Questions and Answers
10:00 am - 10:30am BREAK Location
10:30 am - 11:15am Abbott Nutrition Lecturer
David Keefe MD
Title: Preimplantation Genetic Testing - Past - Present and Future
Transmission of Mendelian diseases can be prevented by testing embryos before transfer - a process called preimplantation genetic diagnosis (PGD).  Preimplantation embryos also harbor a high level of genomic instability -  including numeric chromosome abnormalities copy number variants and insertions/deletions.  Preimplantation genetic testing for aneuploidy (PGT-A or PGS) enhances implantation and decreases miscarriage rates in some patients.  Still 40% of euploid embryos fail to implant.  We are investigating possible contributions of other forms of genomic instability to developmental failure during early human development.
Moderator: Member
Location
11:15am - 11:30am Questions and Answers
11:30 am- 11:50am Abbott Nutrition Early Career Speaker
Speaker

Title:xxx 
Moderator: Member
Location
11:50am - 12:00 noon Questions and Answers
12:00- 12:20pm Abbott Nutrition Early Career Speaker
Speaker

Title: xxx 
Moderator:
Location
12:20pm - 12:30pm Questions and Answers
12:30 pm 2:30pm LUNCH and free time Location
2:30 pm- 3:30pm BUSINESS MEETING Location
3:30pm - 4:15pm Jane Harding ONZM MBCHB DPhil FRCPC FRSNZ
Title: Glucose levels in babies: Too high - too low - too variable - and does it matter 
In older children and adults - the risks of hyper- and hypoglycaemia and their treatment are reasonably well understood.  In the newborn - all of these problems are much more common - but there is little evidence to support any of the currently widely varying treatment approaches.  Recent research is beginning to reveal the long-term sequellae of early dysglycaemia - but there remains much uncertainty about causal relationships and appropriate management.  Moderator
Location
4:15pm - 4:30pm Questions and Answers
4:30pm - 4:50 pm PSANZ-PRS MONT LIGGINS EARLY CAREER SPEAKER
Aidan James Kashyap 
Title: A bundle of care for congenital diaphragmatic hernia - bigger lungs - better vessels - and a smoother transition
Despite standardized neonatal management babies born with congenital diaphragmatic hernia (CDH) continue to face significant mortality and morbidity particularly when respiratory insufficiency is complicated by severe pulmonary hypertension.  Current approaches to antenatal management ve tracheal occlusion which increases lung size but does not completely prevent pulmonary hypertension.  We are investigating novel antenatal therapies that may improve pulmonary vascular development an changes to the timing of umbilical cord clamping that may prevent reactive vasoconstriction during the transition to neonatal life.  We aim to combine these approaches into a bundle of care that ensures all babies diagnosed with CDH and their parents can breathe a little easier.Moderator:
Location
4:50 pm - 5:00 pm Questions and Answers
5:00pm - 7:00pm Salsa making and beer tasting
7:00 pm - 8:00pm Dinner - Awards
7:45 pm Dinner and Trainee Awards Location
8:00pm- 8:45pm March of Dimes Lecturer
Richard Finkel MD 
Title: Genetic modulation strategies for Spinal Muscular Atrophy - current and future treatments
Spin muscular atrophy (SMA) - a progressive degenerative disease affective motor reunions - is the most common fatal genetic disorder of infancy.  Treatment strategies to modulate gene expression have demonstrated remarkable clinical responses in infants and children with SMA.  Data from several clinical trials uniformly indicates that earlier treatment offers the best prospect for a robust response and that pre-sympotomatic treatments appear optimal.  These observations support the effort to add SMA to the newborn screening panel.  If widely endorsed - newborn screening and pre-sympotomatic treatment may virtually extinguish SMA type 1. Moderator:
Location
8:45pm -  9:00pm Questions and Answers

 

Sunday, September 9
Time Event Location
6:45 am - 7:45am BREAKFAST Location
8:00 am - 8:45am NICHD LECTURER
Stephen Kingsmore MD DSC
Title: Perinatal Genomic Medicine.   Genetic diseases re the leading cause of death in infants - NICUs - PICUs and CVICUs.  Rapid whole genome sequencing (rWGS) can improve outcomes of infants in intensive care units by informing targeted treatments of genetic diseases The turnaround time of rWGs - from blood spot to provisional diagnosis - can be less than 20 hours.  Approximately 1/3 of symptomatic infants undergoing rWGs receive a diagnosis.  About 2/3 of infants diagnosed by rWGs ha consequent chage in management - and about 1/3 have decreased mortality or morbidity.  It will be interesting to determine the impact of rWGS on perinatology
Moderator: Member
Location
8:45am - 9:00am Questions and Answers
9:00am - 9:45am Member Lecturer
David Aronoff MD FIDSA FAAM
Title: Paracrine Communication in Bacterial Chorioamnionitis.  Despite this there are significant gaps inour understanding of how these membranes function to protect the developing fetus from infection and whey they sometimes fail.  To better define the pathogenesis of bacterial chorioamnionitis we are deconstructing fetal membranes into component  cell types (both immune and non-immune) and modeling for autocrine and paracrine responses to microbialthreat agents using new systems such as organ-on-chip technologies. 
Moderator: Member
Location
9:45am - 10:00am Questions and Answers
10:00am - 10:15am Break
10:15am - 11:00am MEMBER LECTURER
Jennifer Sucre PhD
Title: Bioengineering Human Lung Development and Disease
While there are excellent mammalian models of lung development and lung disease - there are species-specific differences in the development of the human lung - creating significant knowledge gaps in our understanding of chronic lung disease after preterm birth.  This talk will describe how we have developed a reductionist 3D human model of bronchopulmonary dysplasia and are using this model to gain insights in the molecular pathophysiology of BPD - with a goal of identifying new potential therapeutic targets.  Moderator: Member
Location
11:00am - 11:15am Questions and Answers
11:15am - 12:00 pm MEMBER LECTURER
Emily Su MD MS
Title:Fetoplacental Vessels ARNT Small Business.  Abnormal umbilical artery Doppler velocimetry in growth-restricted fetuses is an ominous finding that substantially increases risk for adverse perinatal and long-term outcomes.  Placentas from these pregnancies of demonstrate impaired fetoplacental angiogenesis.  In a model of an fetopental endothelial cells we have found that arylhydrocarbon receptor nuclear traslocator (ARNT also known as HIF1-bet) is a major mediator of fetoplacental angiogenesis and its decreased expression in severe fetal growth restriction may impair proper development of placental vasculature.
Moderator: Member
Location
12:00pm - 12:15pm Questions and Answers
12:15pm CLOSING REMARKS - Adjournment - Lunch Location